← Eichor
Condition: Bone And Soft Tissue Tumors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Bone And Soft Tissue Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy of Pre-operative Prehabilitation in Patients With Limb Sarcoma
Phase 2 · 1 location(s) · Institut Claudius Regaud · NCT04515459Toripalimab Combined With CAV/IE Regimen
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT04589741T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissu
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06474676Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Phase 1 · 1 location(s) · Florida International University · NCT05857969Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
Phase N/A · 1 location(s) · Henan Cancer Hospital · NCT05468970ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Phase 2 · 11 location(s) · Hansoh BioMedical R&D Company · NCT05830123Single Arm Romiplostim to Prevent CIT
EARLY_Phase 1 · 2 location(s) · Children's Hospital Medical Center, Cincinnati · NCT07048249Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT07675967Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Phase 1 · 1 location(s) · Case Comprehensive Cancer Center · NCT05210374Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07227571A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosar
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07477457Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
NA · 16 location(s) · Centre Leon Berard · NCT04055220Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II
Phase N/A · 1 location(s) · Central Hospital, Nancy, France · NCT04394052Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
Phase 3 · 3 location(s) · Matthew Bucknor · NCT02923011Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Phase 1 · 1 location(s) · Stanford University · NCT06500819Registry of Multiple Osteochondromas
Phase N/A · 1 location(s) · Luca Sangiorgi · NCT04133285Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Phase 1 · 1 location(s) · Ann & Robert H Lurie Children's Hospital of Chicago · NCT06235125Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07066982Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Phase 1 · 1 location(s) · Emory University · NCT06492954InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT05463796Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/Phase 2 · 10 location(s) · St. Jude Children's Research Hospital · NCT04901702NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
Phase 1 · 3 location(s) · Peking University People's Hospital · NCT06340204Musculoskeletal Cancers Remote Monitoring and Care
NA · 1 location(s) · Case Comprehensive Cancer Center · NCT07129226Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplast
Phase 1/Phase 2 · 28 location(s) · National Cancer Institute (NCI) · NCT04616560QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06939855B7-H3 NIR Imaging for Osteosarcoma Surgery
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06778603Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Phase N/A · 19 location(s) · Blueprint Medicines Corporation · NCT07143669A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intr
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06650514Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
Phase 2 · 2 location(s) · Hackensack Meridian Health · NCT05726383
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.